Chronic kidney disease at high altitude

Journal of the American Society of Nephrology

Volumn 19, Issue 12, 2008, Pages 2262-2271

  Luks, Andrew M ^a   Johnson, Richard J ^b   Swenson, Erik R ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DEXAMETHASONE; NIFEDIPINE; SALMETEROL; SILDENAFIL; TADALAFIL;

ALTITUDE; ALTITUDE DISEASE; ARTERIAL HYPOXEMIA; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; HUMAN; HYPOXIA; KIDNEY BLOOD FLOW; KIDNEY INJURY; PHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

EID: 57149108327     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007111199     Document Type: Short Survey

References (105)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003
2. Nangaku M: Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006
3. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C: Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl S46-S51, 2005
4. Fine NG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney disease: from hypothesis to novel therapeutics. Kidney Int 74: 867-872, 2008
5. Swenson ER: Renal function and fluid homeostasis. In: High Altitude: An Exploration of Human Adaptation, edited by Hornbein TF, Schoene RB, New York, Marcel Dekker, 2001, pp 525-568
6. Krapf R, Beeler I, Hertner D, Hulter HN: Chronic respiratory alkalosis: The effect of sustained hyperventilation on renal regulation of acid-base equilibrium. N Engl J Med 324: 1394-1401, 1991
7. Ullmann E: Acute anoxia and the excretion of water and electrolyte. J Physiol 155: 417-437, 1961
8. Loeppky JA, Roach RC, Selland MA, Scotto P, Luft FC, Luft UC: Body fluid alterations during head-down bed rest in men at moderate altitude. Aviat Space Environ Med 64: 265-274, 1993
9. Ashack R, Farber MO, Weinberger MH, Robertson GL, Fineberg NS, Manfredi F: Renal and hormonal responses to acute hypoxia in normal individuals. J Lab Clin Med 106: 12-16, 1985
10. Axelrod DR, Pitts RF: Effects of hypoxia on renal tubular function. J Appl Physiol 4: 593-601, 1952
11. Vidiendal Olsen N, Christensen H, Klausen T, Fogh-Andersen N, Plum I, Kanstrup IL, Hansen JM: Effects of hyperventilation and hypocapnic/normocapnic hypoxemia on renal function and lithium clearance in humans. Anesthesiology 89: 1389-1400, 1998
12. Olsen NV, Kanstrup IL, Richalet JP, Hansen JM, Plazen G, Galen FX: Effects of acute hypoxia on renal and endocrine function at rest and during graded exercise in hydrated subjects. J Appl Physiol 73: 2036-2043, 1992
13. Pauli HG, Truniger B, Larsen JK, Mulhausen RO: Renal function during prolonged exposure to hypoxia and carbon monoxide: II. Electrolyte handling. Scand J Clin Lab Invest Suppl 103: 61-67, 1968
14. Winslow RM, Monge C: Renal function in high-altitude polycythemia. In: Hypoxia, Polycythemia, and Chronic Mountain Sickness, edited by Winslow RM, Monge C, Baltimore, Baltimore, Johns Hopkins University Press, 1987, pp 119-141
15. Lozano R, Monge C: Renal function in high-altitude natives and in natives with chronic mountain sickness. J Appl Physiol 20: 1026-1027, 1965
16. Rennie D, Lozano R, Monge C, Sime F, Whittembury J: Renal oxygenation in male Peruvian natives living permanently at high altitude. J Appl Physiol 30: 450-456, 1971
17. Ou LC, Silverstein J, Edwards BR: Renal function in rats chronically exposed to high altitude. Am J Physiol 247: F45-F49, 1984
18. Brull L, Divry A: Metabolic and secretory activity of the kidney under anoxemia. Arch Int Physiol 58: 415-423, 1951
19. Hansen JM, Olsen NV, Feldt-Rasmussen B, Kanstrup IL, Dechaux M, Dubray C, Richalet JP: Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. J Appl Physiol 76: 1922-1927, 1994
20. Ramirez G, Pineda D, Bittle PA, Rabb H, Rosen R, Vesely D, Sasaki S: Partial renal resistance to arginine vasopressin as an adaptation to high altitude living. Aviat Space Environ Med 69: 58-65, 1998
21. Ramirez G, Bittle PA, Agosti SJ, Dietz J, Colice GL: Salt loading test in a population adapted to moderately high altitude living (3,000 m). Aviat Space Environ Med 64: 831-838, 1993
22. Hohne C, Boemke W, Schleyer N, Francis RC, Krebs MO, Kaczmarczyk G: Low sodium intake does not impair renal compensation of hypoxia-induced respiratory alkalosis. J Appl Physiol 92: 2097-2104, 2002
23. Winterborn MH, Bradwell AR, Chesner IM, Jones GT: The origin of proteinuria at high altitude. Postgrad Med J 63: 179-181, 1987
24. Pines A: High-altitude acclimatization and proteinuria in East Africa. Br J Dis Chest 72: 196-198, 1978
25. Olsen NV, Hansen JM, Kanstrup IL, Richalet JP, Leyssac PP: Renal hemodynamics, tubular function, and response to low-dose dopamine during acute hypoxia in humans. J Appl Physiol 74: 2166-2173, 1993
26. Rosenberg ME, Hostetter TE: Proteinuria. In: The Kidney: Physiology and Pathophysiology, edited by Seldin DW, Giebisch G, New York, Raven, 2000, pp 3039-3061
27. Wada K, Mizuguchi Y, Wada Y, Ohno Y, Iino Y: Hyperlipidaemia, lack of sleep and smoking as risk factors for proteinuria among high altitude mountain trekkers. Nephrology (Carlton) 11: 131-136, 2006
28. Bradwell AR, Delamere JP: The effect of acetazolamide on the proteinuria of altitude. Aviat Space Environ Med 53: 40-43, 1982
29. Eckardt KU, Kurtz A: Regulation of erythropoietin production. Eur J Clin Invest 35[Suppl 3]: 13-19, 2005
30. Schmidt W, Spielvogel H, Eckardt KU, Quintela A, Penaloza R: Effects of chronic hypoxia and exercise on plasma erythropoietin in high-altitude residents. J Appl Physiol 74: 1874-1878, 1993
31. Knaupp W, Khilnani S, Sherwood J, Scharf S, Steinberg H: Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol 73: 837-840, 1992
32. Leichtweiss HP, Lubbers DW, Weiss C, Baumgartl H, Reschke W: The oxygen supply of the rat kidney: Measurements of intrarenal pO2. Pflugers Arch 309: 328-349, 1969
33. Johannes T, Mik EG, Ince C: Dual-wavelength phosphorimetry for determination of cortical and subcortical microvascular oxygenation in rat kidney. J Appl Physiol 100: 1301-1310, 2006
34. Schurek HJ, Jost U, Baumgartl H, Bertram H, Heckmann U: Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Physiol 259: F910-F915, 1990
35. Baumgartl H, Leichtweiss HP, Lubbers DW, Weiss C, Huland H: The oxygen supply of the dog kidney: Measurements of intrarenal pO2. Microvasc Res 4: 247-257, 1972
36. Lubbers DW, Baumgartl H: Heterogeneities and profiles of oxygen pressure in brain and kidney as examples of the pO2 distribution in the living tissue. Kidney Int 51: 372-380, 1997
37. Epstein FH: Oxygen and renal metabolism. Kidney Int 51: 381-385, 1997
38. Evans RG, Gardiner BS, Smith DW, O'Connor PM: Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. Am J Physiol Renal Physiol 2008 Jun 11 [Epub ahead of print]
39. Nakagawa T, Kang DH, Ohashi R, Suga S, Herrera-Acosta J, Rodriguez-Iturbe B, Johnson RJ: Tubulointerstitial disease: Role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 12: 233-241, 2003
40. Leong CL, Anderson WP, O'Connor PM, Evans RG: Evidence that renal arterial-venous oxygen shunting contributes to dynamic regulation of renal oxygenation. Am J Physiol Renal Physiol 292: F1726-F1733, 2007
41. Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ: Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 63: 2088-2093, 2003
42. Johannes T, Mik EG, Nohe B, Unertl KE, Ince C: Acute decrease in renal microvascular PO2 during acute normovolemic hemodilution. Am J Physiol Renal Physiol 292: F796-F803, 2007
43. Nath KA, Croatt AJ, Hostetter TH: Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol 258: F1354-F1362, 1990
44. Welch WJ, Baumgartl H, Lubbers D, Wilcox CS: Nephron pO2 and renal oxygen usage in the hypertensive rat kidney. Kidney Int 59: 230-237, 2001
45. Adler S, Huang H: Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. J Am Soc Nephrol 13: 1788-1794, 2002
46. Haase VH: Hypoxia-inducible factors in the kidney. Am J Physiol 291: F271-F281, 2006
47. Kang DH, Johnson RJ: Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12: 43-49, 2003
48. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ: Impaired angiogenesis in the aging kidney: Vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 37: 601-611, 2001
49. Mairbaurl H, Schobersberger W, Hasibeder W, Knapp E, Hopferwieser T, Humpeler E, Loeffler HD, Wetzels E, Wybitul K, Baumgartl P, et al.: Exercise performance of hemodialysis patients during short-term and prolonged exposure to altitude. Clin Nephrol 32: 31-39, 1989
50. Eschbach JW: Erythropoietin 1991: An overview. Am J Kidney Dis 18: 3-9, 1991
51. Blumberg A, Keller H, Marti HR: Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur J Clin Invest 3: 93-97, 1973
52. Mairbaurl H, Schobersberger W, Hasibeder W, Knapp E, Hopferwieser T, Dittrich P: Increase in Hb-O2-affinity at moderate altitude (2000 m) in patients on maintenance hemodialysis. Clin Nephrol 31: 198-203, 1989
53. Quick J, Eichenberger A, Binswanger U: Stimulation of erythropoietin in renal insufficiency by hypobaric hypoxia. Nephrol Dial Transplant 7: 1002-1006, 1992
54. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 38: 405-416, 2004
55. Bartsch P, Gibbs JS: The effect of altitude on the heart and lungs. Circulation 116: 2191-2202, 2007
56. Hackett PH, Roach RC: High-altitude illness. N Engl J Med 345: 107-114, 2001
57. Bartsch P, Mairbaurl H, Maggiorini M, Swenson ER: Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 98: 1101-1110, 2005
58. Basnyat B Murdoch DR: High-altitude illness. Lancet 361: 1967-1974, 2003
59. Swenson ER: Carbonic anhydrase inhibitors and ventilation: A complex interplay of stimulation and suppression. Eur Respir J 12: 1242-1247, 1998
60. Hackett PH, Roach RC, Schoene RB, Harrison GL, Mills WJ Jr: Abnormal control of ventilation in high-altitude pulmonary edema. J Appl Physiol 64: 1268-1272, 1988
61. King AB, Robinson SM: Ventilation response to hypoxia and acute mountain sickness. Aerosp Med 43: 419-421, 1972
62. Moore LG, Harrison GL, McCullough RE, McCullough RG, Micco AJ, Tucker A, Weil JV, Reeves JT: Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. J Appl Physiol 60: 1407-1412, 1986
63. Lejeune P, Brimioulle S, Leeman M, Hallemans R, Melot C, Naeije R: Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogs. Anesthesiology 73: 256-264, 1990
64. Abassi Z, Nakhoul F, Khankin E, Reisner SA, Yigla M: Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: Pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 15: 353-360, 2006
65. Rios B, Driscoll DJ, McNamara DG: High-altitude pulmonary edema with absent right pulmonary artery. Pediatrics 75: 314-317, 1985
66. Torrington KG: Recurrent high-altitude illness associated with right pulmonary artery occlusion from granulomatous mediastinitis. Chest 96: 1422-1424, 1989
67. Naeije R, De Backer D, Vachiery JL, De Vuyst P: High-altitude pulmonary edema with primary pulmonary hypertension. Chest 110: 286-289, 1996
68. Yu HT: Progression of chronic renal failure. Arch Intern Med 163: 1417-1429, 2003
69. Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58: 2351-2366, 2000
70. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M: Trans-differentiation of cultured tubular cells induced by hypoxia. Kidney Int 65: 871-880, 2004
71. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001
72. Nakanishi K, Tajima F, Nakamura A, Yagura S, Ookawara T, Yamashita H, Suzuki K, Taniguchi N, Ohno H: Effects of hypobaric hypoxia on antioxidant enzymes in rats. J Physiol 489: 869-876, 1995
73. Jefferson JA, Simoni J, Escudero E, Hurtado ME, Swenson ER, Wesson DE, Schreiner GF, Schoene RB, Johnson RJ, Hurtado A: Increased oxidative stress following acute and chronic high altitude exposure. High Alt Med Biol 5: 61-69, 2004
74. Ruggenenti P, Perna A, Mosconi L, Pisoni R Remuzzi G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53: 1209-1216, 1998
75. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919, 1997
76. Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, Brown D, Molitoris BA, Comper WD: The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 71: 504-513, 2007
77. Meyer TW: Tubular injury in glomerular disease. Kidney Int 63: 774-787, 2003
78. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974-2984, 2006
79. Hochman ME, Watt JP, Reid R, O'Brien KL: The prevalence and incidence of end-stage renal disease in Native American adults on the Navajo reservation. Kidney Int 71: 931-937, 2007
80. Sayarlioglu H, Erkoc R, Dogan E, Topal C, Algun E, Erem C, Atmaca H, Kocak E, Yilmaz R, Erdol H, Cinal A: Nephropathy and retinopathy in type 2 diabetic patients living at moderately high altitude and sea level. Ren Fail 27: 67-71, 2005
81. Moore K, Vizzard N, Coleman C, McMahon J, Hayes R, Thompson CJ: Extreme altitude mountaineering and type 1 diabetes: The Diabetes Federation of Ireland Kilimanjaro Expedition. Diabet Med 18: 749-755, 2001
82. Pavan P, Sarto P, Merlo L, Casara D, Ponchia A, Biasin R, Noventa D, Avogaro A: Extreme altitude mountaineering and type 1 diabetes: The Cho Oyu alpinisti in Alta Quota expedition. Diabetes Care 26: 3196-3197, 2003
83. Bender PR, Groves BM, McCullough RE, McCullough RG, Huang SY, Hamilton AJ, Wagner PD, Cymerman A, Reeves JT: Oxygen transport to exercising leg in chronic hypoxia. J Appl Physiol 65: 2592-2597, 1988
84. Wolfel EE, Groves BM, Brooks GA, Butterfield GE, Mazzeo RS, Moore LG, Sutton JR, Bender PR, Dahms TE, McCullough RE, et al.: Oxygen transport during steady-state submaximal exercise in chronic hypoxia. J Appl Physiol 70: 1129-1136, 1991
85. Marticorena E, Ruiz L, Severino J, Galvez J, Penaloza D: Systemic blood pressure in white men born at sea level: Changes after long residence at high altitudes. Am J Cardiol 23: 364-368, 1969
86. Canepa A, Chavez R, Hurtado A, Rotta A, Velasquez T: Pulmonary circulation at sea level and at high altitudes. J Appl Physiol 9: 328-336, 1956
87. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
88. Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis DP, Elisaf MS: Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence. J Cardiovasc Pharmacol Ther 11: 1-15, 2006
89. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48: 8-20, 2006
90. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13: 1206-1210, 1998
91. Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H: The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 45: 59-62, 2003
92. Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J: A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 19: 1871-1876, 2001
93. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37: 890-899, 2001
94. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37: S182-S238, 2001
95. Hussein MM, Bakir N, Roujouleh H: Low-dose recombinant human erythropoietin in dialysis patients living at high altitude. Nephrol Dial Transplant 7: 173-174, 1992
96. Brookhart MA, Schneeweiss S, Avron J, Bardbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmeyer WC: The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol 19: 1389-1395, 2008
97. Luks AM, Swenson ER: Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest 133: 744-755, 2007
98. Bennett WM, Aronoff GR, Golper TA: Drug Prescribing in Renal Failure, Philadelphia, American College of Physicians, 1987
99. Paisley KE, Tomson CR: Calcium phosphate stones during long-term acetazolamide treatment for epilepsy. Postgrad Med J 75: 427-428, 1999
100. Pepys MB: Acetazolamide and renal stone formation. Lancet 1: 837, 1970
101. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Bohm T, Bernheim A, Kiencke S, Bloch KE, Dehnert C, Naeije R, Lehmann T, Bartsch P, Mairbaurl H: Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann Intern Med 145: 497-506, 2006
102. Tadalafil (Cialis® ) US Prescribing Information, Indianapolis, Lilly ICOS LLC, 2006
103. Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, Wrishko RE, Mitchell MI: Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol 63: 24-35, 2007
104. Product Information Revatio® (Sildenafil Citrate) Oral Tabs, New York, Pfizer, 2006
105. Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, Hutter D, Turini P, Hugli O, Cook S, Nicod P, Scherrer U: Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 346: 1631-1636, 2002